Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CETP | P11597 | 1/20 | 0.54 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.48 |
| ▸ | POLB | P06746 | 2/20 | 0.46 |
| ▸ | LMNA | P02545 | 2/20 | 0.46 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.42 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | TP53 | P04637 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL999403 | 0.86 | LMNA (0.55) | CETPL3MBTL1POLBLMNAALDH1A1 | |
| SCHEMBL3774635 | 0.81 | CETP (0.59) | CETPL3MBTL1POLBALDH1A1MEN1 | |
| SCHEMBL9835326 | 0.80 | LMNA (0.54) | CETPPOLBLMNAALDH1A1KDM4E | |
| SCHEMBL5706504 | 0.80 | CETP (0.71) | CETPL3MBTL1POLBLMNAALDH1A1 | |
| SCHEMBL30525296 | 0.79 | CETP (0.59) | CETPL3MBTL1POLBLMNANPSR1 | |
| SCHEMBL10072797 | 0.79 | MAPK1 (0.55) | POLBALDH1A1KDM4EMEN1RAB9A | |
| SCHEMBL12284944 | 0.79 | CETP (0.59) | CETPL3MBTL1POLBLMNANPSR1 | |
| SCHEMBL2209111 | 0.78 | ALDH1A1 (0.49) | CETPL3MBTL1POLBLMNANPSR1 | |
| SCHEMBL9833634 | 0.78 | LMNA (0.55) | CETPPOLBLMNAALDH1A1MEN1 | |
| SCHEMBL16998375 | 0.77 | TRPV1 (0.52) | CETPL3MBTL1POLBLMNANPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120077990-A1 | Alkene Aziridination | NATIONAL SCIENCE FOUNDATION | 2012-03-29 | — | — | US | disclosed |
| US-20110207956-A1 | INTRAMOLECULAR C-H AMINATION WITH PHOSPHORYL AZIDES | NATIONAL SCIENCE FOUNDATION | 2011-08-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110207956-A1 | INTRAMOLECULAR C-H AMINATION WITH PHOSPHORYL AZIDES | CYCS, CCNH, CBR3 | CETP 3963/4885L3MBTL1 4087/4885POLB 783/4885 |
| US-20120077990-A1 | Alkene Aziridination | AZI2, PPOX, GLI2 | CETP 4648/4885L3MBTL1 3523/4885POLB 4562/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.